Alcon: acquisition in dry eye disease in US
(CercleFinance.com) - Alcon announced on Monday that it had reached an agreement to acquire Eysuvis eye drops from US-based Kala Pharmaceuticals.
Approved by the FDA in January 2021, this corticosteroid is indicated for the treatment of patients with dry eyes, for a maximum duration of two weeks.
The agreement also includes Inveltys, Kala's ophthalmic solution for the post-operative treatment of eye surgery patients.
Alcon said Eysuvis generated 6.3 million dollars in revenue last year, while Inveltys had annual sales of 4.9 million dollars.
The Swiss group says it will pay 60 million dollars to complete the deal, with further payments contingent on the achievement of certain commercial milestones.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Approved by the FDA in January 2021, this corticosteroid is indicated for the treatment of patients with dry eyes, for a maximum duration of two weeks.
The agreement also includes Inveltys, Kala's ophthalmic solution for the post-operative treatment of eye surgery patients.
Alcon said Eysuvis generated 6.3 million dollars in revenue last year, while Inveltys had annual sales of 4.9 million dollars.
The Swiss group says it will pay 60 million dollars to complete the deal, with further payments contingent on the achievement of certain commercial milestones.
Copyright (c) 2022 CercleFinance.com. All rights reserved.